8-K: CytoSorbents Executes 1:20 Reverse Stock Split

CytoSorbents Corporation has officially completed a 1-for-20 reverse stock split, effective September 8, 2026, to adjust its issued and outstanding common stock.

Summary

• CytoSorbents Corporation has implemented a 1-for-20 reverse stock split, effective September 8, 2026.
• This action was approved by shareholders at the 2026 Annual Meeting on August 13, 2026.
• The company filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation on September 3, 2026, with the Delaware Secretary of State.
• The reverse stock split automatically reclassified every twenty shares of common stock into one share.
• The par value per share remains $0.001.
• Outstanding options and warrants were proportionally adjusted in number and exercise price.
• No fractional shares were issued; any entitlements were rounded up to the nearest whole share.
• Trading on the Nasdaq Capital Market will continue on a split-adjusted basis starting September 8, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the reverse stock split, which often signals underlying financial distress or a strategy to avoid delisting, despite the company's efforts to frame it as a procedural adjustment.

Positives

• The reverse stock split was approved by shareholders, indicating a level of consensus on the measure.
• The company ensured that fractional shares were rounded up, potentially benefiting smaller shareholders.
• The adjustments to options and warrants were handled automatically, streamlining the process.
• Trading is expected to continue on the Nasdaq Capital Market on a split-adjusted basis, maintaining market access.

Negatives

• A reverse stock split is often a sign of a company's stock price falling below exchange listing requirements or a general struggle to maintain market capitalization.
• The need for a 1:20 split suggests a significant decline in the stock's per-share value prior to this action.
• While not explicitly stated as a reason, reverse splits can be perceived negatively by the market, potentially impacting investor confidence.

Risks

• The primary risk is the market's perception of the reverse stock split, which could lead to continued downward pressure on the stock price.
• Failure to improve underlying business performance could lead to further stock price declines, potentially necessitating future reverse splits or facing delisting.

Future Outlook

The filing does not contain specific forward-looking statements or guidance related to financial performance. The primary forward-looking aspect is the continuation of trading on the Nasdaq on a split-adjusted basis.

Management Comments

• The reverse stock split was approved by the shareholders of the Company at the 2026 Annual Meeting of Stockholders.
• The Board of Directors determined the final ratio within the shareholder-approved range.
• The Company filed a certificate of amendment to amend the Company's Second Amended and Restated Certificate of Incorporation.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often controversial, tool used by companies, particularly those in the biotechnology and medical device sectors, to meet minimum bid price requirements for exchange listings and to make their stock appear more attractive to institutional investors. However, they do not address the underlying business fundamentals.

Corporate Governance

Stakeholder Impact

• Shareholders will hold fewer shares, but the total value of their holdings should remain proportionally the same immediately after the split, assuming no market reaction.
• Holders of options and warrants will see their share counts reduced and exercise prices increased proportionally.
• Brokers and custodians will manage the share adjustments for shareholders holding shares in street name or book-entry form.

Next Steps

• Continue trading on The Nasdaq Stock Market LLC on a split-adjusted basis.
• Shareholders will be notified by Equiniti Trust Company, LLC, the exchange agent, regarding the reverse stock split.

Key Dates

Recommendation

The reverse stock split is a procedural move to maintain Nasdaq listing, not a reflection of improved business fundamentals. While it addresses a potential delisting risk, it doesn't inherently create value. Investors should hold and await evidence of operational improvement or strategic growth before considering a buy, and the move itself doesn't warrant a sell.

Keywords

Reverse Stock Split, Common Stock, Shareholder Approval, Certificate of Amendment, Nasdaq Listing, Stock Adjustment, Corporate Governance